Recombinant Mouse IL-17A (C-6His)
- 货号：EPT207
- 价格：￥1,260.00 元
- 点击：1224
产品介绍
基本信息
| 规格 | 10ug |
|---|
| 表达宿主 | Human Cells |
|---|
| 标签 | C-6His |
|---|
物理性质
| 分子量 | 16.2 KDa |
|---|
| 表观分子量 | 17-26 KDa, reducing conditions |
|---|
| 形态 | Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4. |
|---|
| 纯度 | Greater than 95% as determined by reducing SDS-PAGE. |
|---|
活性与内毒素
| 内毒素水平 | Less than 0.001 ng/µg (0.01 EU/µg) as determined by LAL test. |
|---|
| 活性 | Loaded Biotinylated Human IL-17RA -His-Avi(Cat#CY78) on SA Biosensor, can bind Mouse IL-17A-His(Cat#CX14) with an affinity constant of 12.6 nM as determined in BLI assay. |
|---|
储存与运输
| 溶解方法 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting.
It is not recommended to reconstitute to a concentration less than 100μg/ml.
Dissolve the lyophilized protein in distilled water.
Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
|---|
| 储存方法 | Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks.
Reconstituted protein solution can be stored at 4-7°C for 2-7 days.
Aliquots of reconstituted samples are stable at < -20°C for 3 months. |
|---|
| 运输条件 | The product is shipped at ambient temperature.
Upon receipt, store it immediately at the temperature listed below. |
|---|
详细说明
| 背景说明 | Interleukin-17 is a potent pro-inflammatory cytokine produced by activated memory T cells. There are at least six members of the IL-17 family in humans and in mice. Mature mouse IL-17A shares 61% and 89% amino acid sequence identity with human and rat IL-17A, respectively. As IL-17 shares properties with IL-1 and TNF-alpha, it may induce joint inflammation and bone and cartilage destruction. This cytokine is found in synovial fluids of patients with rheumatoid arthritis, and produced by rheumatoid arthritis synovium. It increases IL-6 production, induces collagen degradation and decreases collagen synthesis by synovium and cartilage and proteoglycan synthesis in cartilage. IL-17 is also able to increase bone destruction and reduce its formation. Blocking of interleukin-17 with specific inhibitors provides a protective inhibition of cartilage and bone degradation. |
|---|
